ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

quemliclustat

Also written as “Quemliclustat” and “AB680”.

Its studies are mostly in Pancreatic Neoplasms · Adenocarcinoma Of Esophagus · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageQuemliclustat: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 20, 20247 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcus Biosciences61 open or runningphase 3since Sep 20, 2024Sep 18, 2018Nov 30, 2030phase 3 · NCT06608927
Gilead Sciencesits history only11 open or runningphase 2since Dec 9, 2022Dec 9, 2022Dec 2027phase 2 · NCT05676931

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Arcus Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2018First study: phase 1 study in Healthy VolunteersFirst studyNCT03677973 · 64 enrolled · Australia
  2. Sep 23, 2019Phase 1 study in Pancreatic NeoplasmsNCT04104672 · 196 enrolled · United States
  3. Sep 29, 2020Phase 1 study in Healthy VolunteersNCT04575311 · 32 enrolled · Australia
  4. Dec 19, 2020Named quemliclustatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AB680
  5. Apr 8, 2022Phase 2 study in Adenocarcinoma Of EsophagusNCT05329766 · 332 enrolled · United States, Canada, Chile and more
  6. Sep 20, 2024Phase 3 study in Pancreatic NeoplasmsNCT06608927 · 610 enrolled · United States, Australia, Austria and more
  7. Jan 16, 2026Phase 1 study in Healthy ParticipantsNCT07364214 · 8 enrolled · United States

Ahead

  1. Nov 30, 2030Primary completion: phase 3 study in Pancreatic NeoplasmsNCT06608927

TargetBeta

NT5E →read by rule
“A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), ”NCIt, by rule

Other programs on NT5E

ProgramCompanyFurthest phaseStudies
oleclumabAstraZenecaphase 38
uliledlimabruletj-biopharma-co-ltdphase 34

Studies

All 6 Arcus Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07364214Healthy Participants · United States1CompletedApr 6, 20268
NCT06608927Pancreatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingNov 30, 2030610
NCT05329766Adenocarcinoma Of Esophagus · United States, Canada, Chile and more2CompletedSep 7, 2026332
NCT04575311Healthy Volunteers · Australia1CompletedSep 22, 202132
NCT04104672Pancreatic Neoplasms · United States1CompletedJul 21, 2026196
NCT03677973Healthy Volunteers · Australia1CompletedAug 19, 201964

How it is read

Names in the registry

  • “Quemliclustat”, 4 entries
  • “AB680”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.